secwatch.observer — SEC 8-K summary
======================================

Issuer:     4D Molecular Therapeutics, Inc. (FDMT)
CIK:        0001650648
Form:       8-K
Filed at:   2025-10-31T23:59:59+00:00
Accession:  0001193125-25-259302
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

4D Molecular Therapeutics (FDMT) signs $85M upfront license deal with Otsuka for 4D-150 in APAC
--------------------------------------------------------------------------------

- Upfront cash payment of $85M from Otsuka; additional cost sharing of at least $50M over next three years.
- Potential regulatory and commercial milestones up to $335.5M, plus tiered double-digit royalties on net sales in APAC.
- Otsuka gains exclusive rights to develop and commercialize 4D-150 for wet AMD and DME in Japan, China, Australia, and other APAC markets.
- Phase 3 study 4FRONT-1 enrollment exceeds expectations: over 200 patients randomized as of Oct 30, 2025.
- FDMT retains full rights outside APAC, including US, Latin America, and Europe.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/0001193125-25-259302-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1650648/000119312525259302/d41653d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-259302

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer